The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.
Study Type
OBSERVATIONAL
Enrollment
347
Number of patients experiencing Adverse Events (AEs)/ Serious Adverse Events (SAEs) after Cabometyx™ administration
Time frame: From baseline until 21 days after the last dose of Cabometyx (up to approximately 52 weeks)
Proportion of patients who had AEs/SAE after Cabometyx™ administration
Time frame: From baseline until 21 days after the last dose of Cabometyx (up to approximately 52 weeks)
Number of AEs/SAEs after Cabometyx™ administration
Time frame: From baseline until 21 days after the last dose of Cabometyx (up to approximately 52 weeks)
Objective response rate
Time frame: From baseline until 21 days after the last dose of Cabometyx (up to approximately 52 weeks)
Progression Free Survival
Time frame: From baseline until 21 days after the last dose of Cabometyx (up to approximately 52 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Korea University Ansan Hospital
Ansan, South Korea
Hallym University Sacred Heart Hospital
Anyang, South Korea
DONG-A University Hospital (Site A)
Busan, South Korea
DONG-A University Hospital (Site B)
Busan, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Daegu Catholic University Medical Center
Daegu, South Korea
Keimyung University Dongsan Hospital (Site A)
Daegu, South Korea
Keimyung University Dongsan Hospital (Site B)
Daegu, South Korea
The Catholic University of Korea, Daejeon ST.Mary's Hospital
Daejeon, South Korea
Chungnam National University Hospital
Daejeon, South Korea
...and 37 more locations